

DDT COA #000006

QUALIFICATION DETERMINATION

Stephen Joel Coons, PhD Executive Director, PRO Consortium Critical Path Institute 1730 E. River Road Tucson, AZ 85718

Email: SJCoons@c-path.org

Dear Dr. Coons:

On behalf on the qualification review team, in reference to your qualification review package submitted May 18, 2018 for the Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD), we have qualified the ADSD and the ANSD as measures of asthma symptoms for use in the context described in the qualification statement. Attached you will find the qualification statement for the ADSD and the ANSD, which describes the instruments and their qualified context of use.

These instruments have demonstrated adequate evidence of content validity and cross-sectional measurement properties. As additional longitudinal data become available, we encourage you to submit this information for review. This review may lead to a revised qualification statement(s) reflecting the complete measurement properties of the ADSD and ANSD. We also ask you to discuss with the Agency how to submit this information when the time is appropriate.

Please note that, at this time, it is recommended to use the ANSD with the ADSD to better characterize the drug effect and understand the measurement properties of each instrument. Further supportive evidence is required to characterize whether these two instruments (ADSD and ANSD) provide different information related to asthma symptoms.

Please contact the COA Staff at <u>COADDTQualification@fda.hhs.gov</u> should you have any questions (refer to DDT COA #000006).

Sincerely,

Elektra Papadopoulos, MD, MPH Associate Director Clinical Outcome Assessments Staff Office of New Drugs Center for Drug Evaluation and Research Banu Karimi-Shah, MD
Deputy Director (Acting)
Division of Pulmonary, Allergy and Rheumatology
Products (DPARP)
Office of New Drugs
Center for Drug Evaluation and Research